Lv51
1570 积分 2024-08-15 加入
Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
1个月前
已完结
Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
1个月前
已关闭
First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara–VCD front‐line therapy
1个月前
已完结
Multidisciplinary supportive care in systemic light chain amyloidosis
1个月前
已完结
KGIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
2个月前
已完结
Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis
2个月前
已完结
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria
3个月前
已完结
Update on B‐cell maturation antigen‐directed therapies in AL amyloidosis
3个月前
已完结
Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/ Refractory Light Chain Amyloidosis Previously Exposed to Daratumumab
3个月前
已完结
Options for Rescue Treatment of Patients with AL Amyloidosis Exposed to Upfront Daratumumab
3个月前
已完结
皖公网安备34019202002308
